ETFs & MarketsFreeZymeworks Price Target Hits $55 Following FDA Milestone
H.C. Wainwright has adjusted its valuation for Zymeworks to $55 per share following a significant FDA regulatory approval. This development signals a potential shift in sentiment for the biotech firm and broader specialized healthcare indices.